The Effect Lactate Administration on Cerebral Blood Flow During Hypoglycemia

Type1diabetes Clinical Trial

Official title:

The Effect of Lactate Administration on Cerebral Blood Flow During Hypoglycemia; Are the Suppressive Effects of Lactate on Counterregulatory Responses to Hypoglycemia Reflected in an Altered CBF Response?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03730909
• Other study ID #: Lactate_CBF
• Status: Recruiting
• Phase: N/A
• Start date: June 11, 2018
• Est. completion date: June 11, 2019

Study information

• Verified date: October 2018
• Source: Radboud University
• Contact: Bastiaan de Galan, PhD
• Phone: 0243613286
• Email: bastiaan.degalan[@]radboud.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is thought that altered brain lactate handling is involved in the development of impaired awareness of hypoglycemia (IAH), i.e. the inability to timely detect hypoglycemia in people with type 1 diabetes (T1DM). Infusion of lactate diminishes symptomatic and hormonal responses to hypoglycemia in patients with normal awareness of hypoglycemia (NAH), resembling the situation of patients with IAH. It is unknown whether this attenuating effect is due to brain lactate oxidation or the result of lactate-induced alterations of global and regional cerebral blood flow (CBF).

Normally, hypoglycemia causes a redistribution of CBF towards the thalamus, from where the sympathetic response to hypoglycemia is coordinated, but in IAH this effect is absent and global CBF is increased. We hypothesize that lactate infusion in patients with NAH will result in blunting of thalamic activation and/or enhanced global CBF. If so, these results may help delineating the pathogenesis of IAH which eventually creates new avenues to protect against the morbidity associated with hypoglycemia and IAH.

Study design: Single-blind placebo controlled, randomized cross-over intervention study Study population: T1DM patients with NAH (n=10) Intervention: On two separate occasions, patients with T1DM and NAH will undergo a hyperinsulinemic euglycemic-hypoglycemic glucose clamp with or without the infusion of exogenous lactate. ASL-MRI will be applied to measure global and regional changes in CBF.

Main study parameters/endpoints: The change in regional thalamic CBF in response to intravenous lactate infusion compared to placebo, during hypoglycemia

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: June 11, 2019
• Est. primary completion date: April 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Diabetes duration = 1 year

• Age: 18-50 years

• Body-Mass Index: 18-30 kg/m2

• HbA1c: 42-75 mmol/mol (6-9%)

• Outcome Clarke questionnaire: 0-1

• Blood pressure: <160/90 mmHg

Exclusion Criteria:

• Inability to provide informed consent

• Use medication other than insulin, except for oral contraceptives or stable thyroxin supplementation therapy

• Presence of any other medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or cardiac failure, known liver disease, anxiety disorders or a history of panic attacks.

• Microvascular complications of T1DM: Proliferative retinopathy, symptomatic diabetic neuropathy (including autonomic neuropathy) or Nephropathy; clinical/overt albuminuria or an estimated glomerular filtration rate <60ml/min/1.73m2.

• MRI contraindications (pregnancy, severe claustrophobia, metal parts in body)

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Hypoglycemia
• Hypoglycemia Unawareness
• Type1diabetes
• Unconsciousness

Intervention

Drug:
• Sodium Lactate
IV infusion
• Sodium chloride
IV infusion

Locations

Country	Name	City	State
Netherlands	Radoud university medical center	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Regional CBF in ml/100g/min measured with ASL-MRI	The change in regional thalamic CBF in response to intravenous lactate infusion compared to placebo, during hypoglycemia	during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)
Secondary	Global CBF in ml/100g/min measured with ASL-MRI	The change in global CBF in response to intravenous lactate infusion	during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)
Secondary	Counterregulatory hormone responses to hypoglycemia	The difference in adrenaline (pmol/L) responses to hypoglycemia during lactate infusion compared to placebo	during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)
Secondary	Symptom responses to hypoglycemia	The difference in symptom responses to hypoglycemia (meausured with a validated questionnaire) during lactate infusion compared to placebo	during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)
Secondary	Measurements of metabolites in cell lysates or supernatants of the cultured immune cells	The effect of lactate administration on immune cell function and metabolism	during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)